Get started
Ardelyx, Inc.Ardelyx, Inc.Ardelyx, Inc.

Ardelyx, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

ARDX trade ideas

ARDX D1::BEST level to BUY 100% gains (SWING)(STOCKS)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates ARDX D1::BEST level to BUY 100% gains (SWING)(STOCKS) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. Tagged as SHORT because I expect more short-term losses before reversal (BULLS). 🔸 Summary and potential trade setup ::: ARDX daily/candle chart chart overview ::: strong bullish chart accumulation ::: buying near range lows makes sense now ::: 100% gains BUY/HOLD setup ::: best reload BULLS is 3.80-4.40 USD ::: TP1 Bulls is 50% gains ::: TP2 Bulls is 100%+ gains ::: targets based on measured move ::: just buy/hold it and get paid ::: 100%+ gains on BUY SIDE medium-term ::: good luck traders 🔸 Supply/Demand Zones ::: N/A ::: N/A 🔸 Other noteworthy technicals/fundies ::: TD9/Combo update: N/A ::: Sentiment mid-term: BULLS/reversal/accumulation ::: Sentiment outlook short-term: BEARS
NASDAQ:ARDXShort
by ProjectSyndicate
4
ARDELYX INC - NASDAQ: $ARDX - Constructive ConsolidationAfter breaking to higher ground a week ago on enormous volume, shares of ARDELYX INC - NASDAQ: ARDX find themselves in constructive consolidation mode digesting the recent run on lower volume as we can observe from the Daily chart above. With the stock trading well above its 20/50 and 200 DMA's on the Daily timeframe, the short-term technical posture of ARDX remains favorable. While the stock may require additional consolidation in order to absorb its recent sharp move and allow itself to build cause/energy before its next attempt at loftier levels, ARDX continues to shape-up technically. Moving forward, both investors/traders may want to continue to closely monitor the action in ARDX as we suspect that after its current period of consolidation resolves, we may just witness another move into northern territory with and initial objective of $8 and the potential for a secondary objective in the $11-$15 range down the road. Thus, investors/traders may want to put ARDX front-and-center on their radars.
NASDAQ:ARDX
by InsiderFinancial
ARDX Trade idea05:13 Piper still sees 'substantial upside' in Ardelyx despite last week's rally Piper Jaffray analyst Christopher Raymond says he still expects "substantial upside" in shares of Ardelyx even after last week's 43% move. While Amplify's more "real world" representation assuaged the key investor concern around tenapanor's adverse event-related discontinuations, the market still hasn't grasped tenapanor's full market potential in the renal setting, Raymond tells investors in a research note. Feedback from a recent nephrologist survey indicates "significant" awareness, interest and willingness to prescribe tenapanor, adds the analyst. He sees the drug's revenue potential "at well" over $1B in the U.S. alone. As such, Raymond continues to view his $15 target as a "more appropriate valuation" than current share levels. He maintains an Overweight rating on Ardelyx.
NASDAQ:ARDX
by DT-21
ARDX - Perfect Retracement - Bullish Momentum Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipation. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA. P/E Current -1.32 P/E Ratio (with extraordinary items) -1.30 SHORT INTEREST 414.63K 07/31/19 Average Recommendation: BUY Average Target Price: 10.75
NASDAQ:ARDXLong
by DEXWireNews
1